Abstract:Background: When ovarian carcinoma is diagnosed in stage I, up to 90% of patients can be cured with surgery and currently available chemotherapy. At present, less than 25% of cases are diagnosed at this stage. To increase the fraction of ovarian cancers detected at an early stage, screening strategies have been devised that utilize a rising serum CA125 level to trigger the performance of transvaginal sonography. One limitation of CA125 as an initial step in such a screening strategy is that up to 20% of ovarian cancers lack expression of the antigen. Serum tumor markers that can be detected in ovarian cancers that lack CA125 expression might improve the sensitivity for early detection. Methods: From 296 ovarian cancers, 65 (22%) were found to have weak or absent CA125 expression on immunoperoxidase staining. Tissue expression of CA125 was compared to serum CA125 levels. Using immunoperoxidase staining of tissue arrays, we have assessed expression of 10 potential serum tumor markers in the 65 epithelial ovarian cancers with little or no CA125 expression and in ovarian cystadenomas, tumors of low malignant potential, normal ovaries, and 16 other normal tissues. Results: Low or absent expression of CA125 in surgical specimens of epithelial ovarian cancer was associated with low levels of serum CA125 in pre-operative serum specimens. In ovarian cancers that lacked CA125, all specimens (100%) expressed human kallikrein 10 (HK10), human kallikrein 6 (HK6), osteopontin (OPN), and claudin 3. A smaller fraction of CA125-deficient ovarian cancers expressed DF3 (95%), vascular endothelial growth factor (VEGF) (81%), MUC1 (62%), mesothelin (MES) (34%), HE4 (32%), and CA19-9 (29%). When reactivity with normal tissues was considered, however, MES and HE4 showed the greatest specificity. Differential expression was also found for HK10, OPN, DF3, and MUC1. Conclusions: At the level of tissue expression, each of 10 potential serum markers could be detected in 29-100% of ovarian cancers that had low or absent expression of CA125. Several markers exhibited more intense expression in cancers than in normal organs. Further investigation is needed to demonstrate complementary expression of markers in serum.

Evaluation of Serum CA125 in Diagnosis of Epithelial Ovarian Carcinoma

Clinical evaluation of serum CA-125 concentrations in ovary endometriosis patients

[Value of Serum CA(125) Detection for Predicting Recurrence and Prognosis in Ovarian Epithelial Cancer].

The Clinical Implication of Serum CA125 Assay in Endometrial Carcinoma Patients

The Prognostic Value of the Serum CA125 Detection in Patients with Epithelial Ovarian Carcinoma

Evaluation of Serum CA125-Tn Glycoform in Peritoneal Dissemination and Surgical Completeness of High-Grade Serous Ovarian Cancer

The Comparison of CA125 Alone and Multiterm Tumor Index Combined Detection in the Diagnosis of Ovarian Cancer

The clinical significance of the serum CA125 level in ovarian cancer

Ovarian fibroma/fibrothecoma with elevated serum CA125 level: A cohort of 66 cases.

Clinical Significance of Combined Detection of HE4 and CA125 in the Serum and Tumor Tissues of Patients with Ovarian Cancer

Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer

Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer

The role of CA125 in clinical practice

The Predictive Value of B Ultrasound and Serum CA_(125) for Ovarian Malignant Neoplasm in Postmenopausal Women

[Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].

Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis

Potential markers that complement expression of CA125 in epithelial ovarian cancer

The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma

CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels

Relationship Between the Kinetics of Serum CA125 and the Prognosis of Epithelial Ovarian Carcinoma Patients